Neuraly
Neuraly is a clinical-stage biotechnology company dedicated to developing revolutionary treatments for neurodegenerative diseases such as Parkinson’s and Alzheimer’s. The company focuses on addressing new pathways and leveraging innovative science to create disease-modifying therapies that can change lives. With a strong scientific platform and a talented team, Neuraly aims to be a leader in discovering and developing breakthrough medicines.
Industries
Nr. of Employees
small (1-50)
Products
BBB-penetrant, long-acting GLP-1R agonist therapeutic (peptide analogue)
A pegylated peptide analogue designed to penetrate the blood–brain barrier and engage GLP-1 receptors on glial cells to reduce neuroinflammation and protect neurons; advanced in clinical development for Parkinson’s disease and Alzheimer’s disease.
Orally active, BBB-penetrant kinase inhibitor small-molecule series
A program of orally active small-molecule kinase inhibitors designed to penetrate the CNS and inhibit glial activation; lead candidates are in IND-enabling evaluation.
Orally active neuroprotective small-molecule program targeting parthanatos cascade
Discovery-stage small molecules that target parthanatos-related pathways to promote neuronal survival; currently in lead optimization and preclinical development.
BBB-penetrant, long-acting GLP-1R agonist therapeutic (peptide analogue)
A pegylated peptide analogue designed to penetrate the blood–brain barrier and engage GLP-1 receptors on glial cells to reduce neuroinflammation and protect neurons; advanced in clinical development for Parkinson’s disease and Alzheimer’s disease.
Orally active, BBB-penetrant kinase inhibitor small-molecule series
A program of orally active small-molecule kinase inhibitors designed to penetrate the CNS and inhibit glial activation; lead candidates are in IND-enabling evaluation.
Orally active neuroprotective small-molecule program targeting parthanatos cascade
Discovery-stage small molecules that target parthanatos-related pathways to promote neuronal survival; currently in lead optimization and preclinical development.
Services
Sponsor-led clinical development and trial operations
Sponsorship and operational management of clinical trials for neurodegenerative disease programs, including Phase II studies and patient enrollment management.
Biomarker and imaging development with licensing pathways
Development of imaging biomarkers for neuroinflammation and execution of research license and commercialization option agreements.
Assay development and validation for neuroinflammation research
Development and validation of assays to quantify microglial activation, astrocyte responses, inflammatory cytokines, and neuronal viability.
Translational research collaborations
Collaborative sponsored research with academic institutions to evaluate therapeutic candidates in disease-relevant models and translate findings toward clinical development.
Sponsor-led clinical development and trial operations
Sponsorship and operational management of clinical trials for neurodegenerative disease programs, including Phase II studies and patient enrollment management.
Biomarker and imaging development with licensing pathways
Development of imaging biomarkers for neuroinflammation and execution of research license and commercialization option agreements.
Assay development and validation for neuroinflammation research
Development and validation of assays to quantify microglial activation, astrocyte responses, inflammatory cytokines, and neuronal viability.
Translational research collaborations
Collaborative sponsored research with academic institutions to evaluate therapeutic candidates in disease-relevant models and translate findings toward clinical development.
Expertise Areas
- Clinical trial management
- Neurodegenerative therapeutics
- Translational medicine
- Biomarker development and imaging
Key Technologies
- Blood–brain barrier (BBB) penetrant therapeutics
- Long-acting peptide analogues (pegylated formulations)
- GLP-1 receptor agonist modality
- Brain-penetrant kinase inhibitors